By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-225-2860


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. or follow ARIAD on Twitter (@ARIADPharm).

Key Statistics

Ownership: Public

Web Site: Ariad
Symbol: ARIA


Company News
Ariad (ARIA) Announces FDA Full Approval And Label Update For Iclusig (Ponatinib) Based On Long-Term Efficacy And Safety Data From Phase 2 PACE Clinical Trial 11/29/2016 10:48:21 AM
Ariad (ARIA) Announces Data Presentations At The World Conference On Lung Cancer 11/17/2016 11:53:52 AM
Ariad (ARIA) Announces Launch Of Inaugural ALK+ Day During Lung Cancer Awareness Month 11/14/2016 11:33:54 AM
Ariad (ARIA) Reports Third Quarter 2016 Financial Results 11/7/2016 10:43:28 AM
Ariad (ARIA) Announces U.S. FDA Acceptance Of NDA Filing For Brigatinib 10/31/2016 11:55:45 AM
Ariad (ARIA) Announces Publication Of The Preclinical Profile Of Brigatinib In The Journal Clinical Cancer Research 10/26/2016 10:13:25 AM
Ariad (ARIA) Could Follow Gilead (GILD)'s — Or Mylan (MYL)'s — Route In Drug Price Battle 10/25/2016 7:15:02 AM
Bernie Sanders Demands Info on Ariad (ARIA)'s Leukemia Drug 10/21/2016 5:52:35 AM
How One Tweet From Bernie Sanders Sent Ariad (ARIA)'s Stock Plunging 10/17/2016 5:56:21 AM
Ariad (ARIA) Presents Updated Long-Term Follow-Up Results From The Phase 1/2 Trial On Investigational Drug Brigatinib At 2016 ESMO Meeting 10/10/2016 11:42:55 AM